Financials
Financial year 2025
Clinical Research Vanackere from Tielt-Winge, company number BE0656693859, closed financial year 2025 with a result of € 45,633 after tax. For that financial year Clinical Research Vanackere recorded a gross margin of € 89,440 and equity of € 180,771. Compared with financial year 2024, the result moved from € 16,645 to € 45,633. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.
€ 180,771
▲ 34% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 45,633
▲ 174% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 174,571.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 41,927
▼ 31% vs 2024
Of which on lease € 33,697.
Debts at end 2025
€ 66,393
▼ 26% vs 2024
€ 34,107 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 1,188
▼ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,576
▲ € 14,034 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 32,934 | € 54,054 | € 50,777 | € 89,440 | ▲ 76% |
| Profit after taxes | € 19,648 | € 22,622 | € 16,645 | € 45,633 | ▲ 174% |
| Equity | € 143,120 | € 151,232 | € 135,137 | € 180,771 | ▲ 34% |
| Total debts | € 55,942 | € 80,698 | € 95,753 | € 83,156 | ▼ 13% |
| Cash | € 8,194 | € 1,006 | € 0 | - | |
| Retained profit | € 136,920 | € 145,032 | € 128,937 | € 174,571 | ▲ 35% |
| Dividend | € 6,655 | € 14,510 | € 32,740 | € 0 | ▼ 100% |
| Bank debt | € 36,099 | € 75,600 | € 89,811 | € 66,393 | ▼ 26% |
| Balance sheet total | € 199,063 | € 231,931 | € 230,891 | € 263,927 | ▲ 14% |
By gross margin, Clinical Research Vanackere ranks 7th of 12 companies with main activity “Vervaardiging van farmaceutische grondstoffen” in Flemish Brabant that publish figures (fiscal year 2025).
Key figures of Clinical Research Vanackere, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Clinical Research Vanackere the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Clinical Research Vanackere?
What happened at Clinical Research Vanackere in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 45,633 (▲ 174% vs 2024). Source: NBB ↗
- New establishment in Tielt-Winge. KBO
- Birgit Vanackere became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 19,648 profit in 2022 to € 45,633 profit in 2025.
Paid € 47,461 in corporate taxes since 2022.
Best year ever: 2025, with € 45,633 profit.
Paid out € 53,905 in dividends to the owners in total.
Management
Behind Clinical Research Vanackere is Birgit Vanackere.
Directors
According to the 2025 annual accounts
Birgit Vanackere
Director
since 2016
Establishments
Establishment units
Physical locations of this company
Kriebekestraat 1B
3390 Tielt-Winge
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Flemish Brabant
Same main activity (Vervaardiging van farmaceutische grondstoffen), 17 active companies in Flemish Brabant, largest first.
€ 44.9 million revenue · 2025 · Hoeilaart
Dokterspraktijk Marten Geyskens
€ 743,980 gross margin · 2025 · Scherpenheuvel-Zichem
€ 461,063 gross margin · 2025 · Affligem
€ 421,384 revenue · 2025 · Diest
€ 364,405 gross margin · 2024 · Diest
€ 320,026 gross margin · 2025 · Leuven
Details
- Company number
- 0656.693.859
- VAT number
- BE 0656.693.859
- Registered office
- Kriebekestraat 1B, 3390 Tielt-Winge
- Names & denominations
- Clinical Research Vanackere · CRV
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 June 2016
- Peppol
- Active · Active since 11 Feb 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Markt- en opinieonderzoek
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Holdings
Overige gespecialiseerde wetenschappelijke en technische activiteiten
+2